Nuveen
LTGO

Nuveen’s Latigo Biotherapeutics LTGO Stock Holding History

Nuveen’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.04K Buy
+389
New +$8.21K ﹤0.01% 4609

Other funds holding LTGO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Nuveen's LTGO Position: Q3 2026 in Review

Nuveen opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 389 shares worth $7.04K. The stake represents ﹤0.01% of the portfolio and ranks #4609 among its holdings.

9 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Nuveen held 389 shares of Latigo Biotherapeutics worth $7.04K as of Q3 2026.
  • Latigo Biotherapeutics was a new Nuveen position in Q3 2026.
  • Latigo Biotherapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4609 holding.
  • 9 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.